7.99
-0.42 (-5.04%)
| Previous Close | 8.41 |
| Open | 8.21 |
| Volume | 418,736 |
| Avg. Volume (3M) | 1,091,331 |
| Market Cap | 729,240,128 |
| Price / Earnings (Forward) | 125.00 |
| Price / Sales | 1.05 |
| Price / Book | 1.27 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -15.20% |
| Operating Margin (TTM) | -8.22% |
| Diluted EPS (TTM) | -1.41 |
| Quarterly Revenue Growth (YOY) | 7.10% |
| Total Debt/Equity (MRQ) | 20.01% |
| Current Ratio (MRQ) | 1.82 |
| Operating Cash Flow (TTM) | -8.70 M |
| Levered Free Cash Flow (TTM) | 13.25 M |
| Return on Assets (TTM) | -5.06% |
| Return on Equity (TTM) | -17.15% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Myriad Genetics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -2.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.30 |
|
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 2.17% |
| % Held by Institutions | 104.02% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Glenview Capital Management, Llc | 31 Dec 2024 | 4,157,324 |
| Earnest Partners Llc | 31 Dec 2024 | 3,971,598 |
| Camber Capital Management Lp | 31 Dec 2024 | 3,100,000 |
| Disciplined Growth Investors Inc /Mn | 31 Dec 2024 | 2,556,579 |
| Sei Investments Co | 31 Dec 2024 | 2,526,761 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 29.00 (Craig-Hallum, 263.11%) | Buy |
| Median | 18.50 (131.64%) | |
| Low | 11.00 (B of A Securities, 37.73%) | Sell |
| Average | 18.19 (127.76%) | |
| Total | 5 Buy, 2 Hold, 1 Sell | |
| Avg. Price @ Call | 11.40 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 01 Apr 2025 | 20.00 (150.42%) | Buy | 8.84 |
| Piper Sandler | 12 Mar 2025 | 12.50 (56.51%) | Buy | 10.41 |
| 04 Mar 2025 | 11.50 (43.99%) | Hold | 10.42 | |
| B of A Securities | 03 Mar 2025 | 11.00 (37.73%) | Sell | 10.39 |
| Raymond James | 25 Feb 2025 | 19.00 (137.90%) | Buy | 11.74 |
| UBS | 25 Feb 2025 | 16.00 (100.34%) | Hold | 11.74 |
| Craig-Hallum | 12 Feb 2025 | 29.00 (263.11%) | Buy | 13.09 |
| Goldman Sachs | 28 Jan 2025 | 18.00 (125.38%) | Buy | 12.50 |
| Stephens & Co. | 16 Jan 2025 | 20.00 (150.42%) | Hold | 12.52 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ANCONA MARGARET | - | 10.01 | -2,622 | -26,246 |
| DIAZ PAUL J | - | 10.00 | -117,680 | -1,176,623 |
| HAAS KEVIN RICHARD | - | 10.00 | -9,088 | -90,884 |
| MUNK NATALIE | - | 10.00 | -2,545 | -25,446 |
| MUZZEY DALE | - | 10.00 | -8,690 | -86,947 |
| VERRATTI MARK | - | 10.00 | -7,690 | -76,896 |
| Aggregate Net Quantity | -148,315 | |||
| Aggregate Net Value ($) | -1,483,041 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 10.00 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DIAZ PAUL J | Officer | 24 Mar 2025 | Disposed (-) | 45,139 | 9.98 | 450,487 |
| VERRATTI MARK | Officer | 24 Mar 2025 | Disposed (-) | 2,701 | 9.98 | 26,956 |
| MUZZEY DALE | Officer | 24 Mar 2025 | Disposed (-) | 1,345 | 9.98 | 13,423 |
| HAAS KEVIN RICHARD | Officer | 24 Mar 2025 | Disposed (-) | 2,901 | 9.98 | 28,952 |
| MUNK NATALIE | Officer | 24 Mar 2025 | Disposed (-) | 982 | 9.98 | 9,800 |
| DIAZ PAUL J | Officer | 22 Mar 2025 | Disposed (-) | 72,541 | 10.01 | 726,135 |
| VERRATTI MARK | Officer | 22 Mar 2025 | Disposed (-) | 4,989 | 10.01 | 49,940 |
| MUZZEY DALE | Officer | 22 Mar 2025 | Disposed (-) | 7,345 | 10.01 | 73,523 |
| HAAS KEVIN RICHARD | Officer | 22 Mar 2025 | Disposed (-) | 6,187 | 10.01 | 61,932 |
| MUNK NATALIE | Officer | 22 Mar 2025 | Disposed (-) | 1,563 | 10.01 | 15,646 |
| ANCONA MARGARET | Officer | 22 Mar 2025 | Disposed (-) | 2,622 | 10.01 | 26,246 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |